728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic
GITELMAN S, HEROLD K, SIMMONS K, SUMNIK Z, KNECHT L, NIEMOELLER E, TIAN W, COMER G, MILLER D, RAMOS E. 728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic. Diabetes 2024, 73 DOI: 10.2337/db24-728-p.Peer-Reviewed Original ResearchPBO groupTeplizumab groupAnti-CD3 monoclonal antibodyStudy drug discontinuationRates of overall infectionHumanized anti-CD3 monoclonal antibodyIncidence of infectionType 1 diabetesAdministered 6 monthsDrug discontinuationImmunomodulatory therapyTeplizumabAntiviral treatmentModified doseStudy visitsOverall infectionProtocol deviationsMonoclonal antibodiesTreatment groupsInfectionTherapyAged 8COVID-19COVID-19 testingTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply